Nanome

Nanome

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Nanome is a private, San Diego-based company founded in 2015 that provides a spatial computing and AI software platform for scientific research and drug discovery. Its technology combines immersive virtual reality (Nanome XR) for 3D molecular visualization and collaboration with an AI-powered conversational interface (MARA) for managing chemical data and computational workflows. The company targets enterprise customers in the pharmaceutical and biotechnology sectors, as well as academic institutions, with a platform-as-a-service business model, positioning itself as a productivity-enhancing tool rather than a drug developer. Nanome has demonstrated validation through published studies and testimonials from top-tier pharmaceutical companies.

AI / Machine LearningDrug Delivery

Technology Platform

Combined virtual reality (XR) spatial computing platform (Nanome XR) and an AI-powered conversational data interface (MARA) for molecular visualization, collaborative drug design, and scientific data management.

Funding History

2
Total raised:$18M
Series A$15M
Seed$3M

Opportunities

The high cost and long timelines of drug discovery create strong demand for productivity-enhancing tools.
The convergence of AI adoption in biotech and the maturation of VR/AR hardware presents a major opportunity for Nanome's integrated platform to become a standard interface for interactive, data-driven molecular science.

Risk Factors

Key risks include slower-than-expected adoption of VR in daily research workflows due to hardware and cultural barriers, and competition from established molecular software suites adding similar features.
As a private company, it also faces execution risks in enterprise sales and requires continued funding to scale.

Competitive Landscape

Nanome competes with traditional 2D molecular visualization and modeling software suites (e.g., from Schrödinger, Dassault Systèmes BIOVIA, OpenEye). It also faces emerging competition from other VR/AR science startups and potential disruption from large tech companies (e.g., NVIDIA) developing platforms for scientific simulation and collaboration. Its differentiator is the deep integration of immersive collaboration with an AI data copilot.